PURPOSE: We investigated the efficacy of contralateral prophylactic mastectomy (CPM) in reducing contralateral breast cancer incidence and breast cancer mortality among women who have already been diagnosed with breast cancer. METHODS: This retrospective cohort study comprised approximately 50,000 women who were diagnosed with unilateral breast cancer during 1979 to 1999. Using computerized data confirmed by chart review, we identified 1,072 women (1.9%) who had CPM. We obtained covariate information for these women and for a sample of 317 women who did not undergo CPM. RESULTS: The median time from initial breast cancer diagnosis to the end of follow-up was 5.7 years. Contralateral breast cancer developed in 0.5% of women with CPM, metastatic disease developed in 10.5%, and subsequent breast cancer developed in 12.4%; 8.1% died from breast cancer. Contralateral breast cancer developed in 2.7% of women without CPM, and 11.7% died of breast cancer. After adjustment for initial breast cancer characteristics, treatment, and breast cancer risk factors, the hazard ratio (HR) for the occurrence of contralateral breast cancer after CPM was 0.03 (95% CI, 0.006 to 0.13). After adjustment for breast cancer characteristics and treatment, the HRs for the relationship of CPM with death from breast cancer, with death from other causes, and with all-cause mortality were 0.57 (95% CI, 0.45 to 0.72), 0.78 (95% CI, 0.57 to 1.06), and 0.60 (95% CI, 0.50 to 0.72), respectively. CONCLUSION: CPM seems to protect against the development of contralateral breast cancer, and although women who underwent CPM had relatively low all-cause mortality, CPM also was associated with decreased breast cancer mortality.
PURPOSE: We investigated the efficacy of contralateral prophylactic mastectomy (CPM) in reducing contralateral breast cancer incidence and breast cancer mortality among women who have already been diagnosed with breast cancer. METHODS: This retrospective cohort study comprised approximately 50,000 women who were diagnosed with unilateral breast cancer during 1979 to 1999. Using computerized data confirmed by chart review, we identified 1,072 women (1.9%) who had CPM. We obtained covariate information for these women and for a sample of 317 women who did not undergo CPM. RESULTS: The median time from initial breast cancer diagnosis to the end of follow-up was 5.7 years. Contralateral breast cancer developed in 0.5% of women with CPM, metastatic disease developed in 10.5%, and subsequent breast cancer developed in 12.4%; 8.1% died from breast cancer. Contralateral breast cancer developed in 2.7% of women without CPM, and 11.7% died of breast cancer. After adjustment for initial breast cancer characteristics, treatment, and breast cancer risk factors, the hazard ratio (HR) for the occurrence of contralateral breast cancer after CPM was 0.03 (95% CI, 0.006 to 0.13). After adjustment for breast cancer characteristics and treatment, the HRs for the relationship of CPM with death from breast cancer, with death from other causes, and with all-cause mortality were 0.57 (95% CI, 0.45 to 0.72), 0.78 (95% CI, 0.57 to 1.06), and 0.60 (95% CI, 0.50 to 0.72), respectively. CONCLUSION: CPM seems to protect against the development of contralateral breast cancer, and although women who underwent CPM had relatively low all-cause mortality, CPM also was associated with decreased breast cancer mortality.
Authors: Min Yi; Kelly K Hunt; Banu K Arun; Isabelle Bedrosian; Angelica Gutierrez Barrera; Kim-Anh Do; Henry M Kuerer; Gildy V Babiera; Elizabeth A Mittendorf; Kaylene Ready; Jennifer Litton; Funda Meric-Bernstam Journal: Cancer Prev Res (Phila) Date: 2010-07-20
Authors: Regina Kroiss; V Winkler; K Kalteis; D Bikas; M Rudas; M Tea; C Fuerhauser; D Muhr; H Cerny; S Glueck; E Petru; H Concin; E Kubista; P Oefner; T Wagner Journal: J Cancer Res Clin Oncol Date: 2008-04-08 Impact factor: 4.553
Authors: Oluwadamilola Motunaryo Fayanju; Carolyn R T Stoll; Susan Fowler; Graham A Colditz; Julie A Margenthaler Journal: Ann Surg Date: 2014-12 Impact factor: 12.969
Authors: A Bouchard-Fortier; N N Baxter; R Sutradhar; K Fernandes; X Camacho; P Graham; M L Quan Journal: Curr Oncol Date: 2018-12-01 Impact factor: 3.677
Authors: Min Yi; Funda Meric-Bernstam; Lavinia P Middleton; Banu K Arun; Isabelle Bedrosian; Gildy V Babiera; Rosa F Hwang; Henry M Kuerer; Wei Yang; Kelly K Hunt Journal: Cancer Date: 2009-03-01 Impact factor: 6.860
Authors: Marc D Schwartz; Heiddis B Valdimarsdottir; Tiffani A DeMarco; Beth N Peshkin; William Lawrence; Jessica Rispoli; Karen Brown; Claudine Isaacs; Suzanne O'Neill; Rebecca Shelby; Sherry C Grumet; Margaret M McGovern; Sarah Garnett; Heather Bremer; Suzanne Leaman; Kathryn O'Mara; Sarah Kelleher; Kathryn Komaridis Journal: Health Psychol Date: 2009-01 Impact factor: 4.267
Authors: Bettina Meiser; Kathy Tucker; Michael Friedlander; Kristine Barlow-Stewart; Elizabeth Lobb; Christobel Saunders; Gillian Mitchell Journal: Breast Cancer Res Date: 2008-11-28 Impact factor: 6.466